VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax of -$51.55 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2019-12-31 was -$20.82M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2019-09-30 was $12.81M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2019-06-30 was -$5.78M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2020 was -$51.55M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2019 was -$14.00M, a 151.04% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2018 was $27.44M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$51.55M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | -$20.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$8.01M derived: sum of 2 quarters · filed 2021-02-11 | -$13.78M derived: sum of 3 quarters · filed 2021-02-11 | -$14.00M 10-K · filed 2021-02-11 |
| 2019-09-30 | $12.81M 10-Q · filed 2019-10-31 | $7.04M derived: sum of 2 quarters · filed 2019-10-31 | $6.81M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | -$5.78M 10-Q · filed 2019-08-01 | -$6.00M 10-Q · filed 2019-08-01 | ||
| 2018-12-31 | $27.44M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |